Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 44% if caught early, dropping down to 3% if it metastasizes. This is largely due to its ability to elude detection.
The CDC estimates that over 6 million people in the U.S. struggle with OUD, and prior research has indicated that only 20% receive treatment for the disorder.
Patients with asymmetries on CEM typically are recalled for additional views, ultrasound and occasionally MRI. But the extra workup might not be necessary.
A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Treating AFib with surgical ablation during mitral valve surgery and other common heart operations can help patients live longer, a new meta-analysis confirmed.
Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.
Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Palliative care is a recommended part of heart failure management in the U.S., but consultation rates remain low. The trend appears to impact Black patients more than other races and ethnicities.
